T-CAST: An optimized CAST-Seq pipeline for TALEN confirms superior safety and efficacy of obligate-heterodimeric scaffolds.

Rhiel, Manuel; Geiger, Kerstin; Andrieux, Geoffroy; Rositzka, Julia; Boerries, Melanie; Cathomen, Toni; Cornu, Tatjana I

Rhiel, Manuel; Geiger, Kerstin; Andrieux, Geoffroy; Rositzka, Julia; Boerries, Melanie; Cathomen, Toni; Cornu, Tatjana I.

Afiliação

Rhiel M; Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, Freiburg, Germany.
Geiger K; Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Freiburg, Germany.
Andrieux G; Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, Freiburg, Germany.
Rositzka J; Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Freiburg, Germany.
Boerries M; Ph.D. Program, Faculty of Biology, University of Freiburg, Freiburg, Germany.
Cathomen T; Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Cornu TI; German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Front Genome Ed ; 5: 1130736, 2023.

Article em En | MEDLINE | ID: mdl-36890979

Palavras-chave

FokI; TALEN; chromosomal rearrangements; chromosomal translocations; designer nuclease; obligate heterodimer; off-target effects; preclinical risk assessment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Genome Ed Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google